MeMed Secures National Grant to Build AI-Ready Acute-Care Diagnostics Biobank

New updates have been reported about MeMed.

MeMed has been awarded a competitive national grant from the Israel Innovation Authority to create a first-of-its-kind acute-care diagnostics and proteomics biobank, positioning the company at the center of Israel’s emerging nationwide AI R&D data infrastructure for healthcare. The multimillion-dollar initiative is designed to materially accelerate development and regulatory-grade validation of MeMed’s next-generation Artificial Intelligence In Vitro Diagnostics (AIVD™) for high-risk patients by integrating acute-care biospecimens, linked clinical data, and high-resolution immune profiling. By capturing host-response biology at the exact point when clinicians must make rapid, high-stakes decisions in emergency and acute-care settings, the biobank is expected to shorten development timelines, reduce costs, and strengthen MeMed’s competitive moat in AI-enabled diagnostics.

The program builds on MeMed’s existing FDA-level development capabilities and commercialized host-response platform, including MeMed BV®, which is FDA-cleared to distinguish bacterial from viral infections in 15 minutes, and MeMed Severity™, which holds FDA Breakthrough Device Designation for predicting severe outcomes and mortality risk in patients with acute infections and suspected sepsis. Management frames the grant as strategic validation of MeMed’s technology and execution capabilities, with CEO and Co-Founder Eran Eden stating that the infrastructure and expertise to drive this initiative are already in place, and CTO Barak Hershkovitz emphasizing that unifying deep immune-response data with clinical information and AI will move AIVD™ from concept into real-time clinical decision support. For executives and investors, the grant underpins MeMed’s role as a scalable platform for AI-driven acute-care innovation, supports the transition from conventional IVD to intelligent diagnostics, and could enhance the company’s long-term monetization potential through differentiated products, data assets, and partnerships in the acute and emergency care market.